Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S485-S497

  Tebbens, Radboud J Duintjer ^a   Thompson, Kimberly M ^a,b  

^a Kid Risk Inc   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

disease outbreaks; dynamic modeling; eradication; inactivated poliovirus vaccine; oral poliovirus vaccine; polio

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; CIRCULATING VACCINE DERIVED POLIOVIRUS; DRUG COST; DRUG DOSE REGIMEN; DRUG USE; DRUG WITHDRAWAL; EPIDEMIC; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; INCIDENCE; NONBIOLOGICAL MODEL; ORAL POLIOVIRUS VACCINE EVOLUTION MODEL; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; POPULATION DYNAMICS; POPULATION IMMUNITY; PROBABILITY; RISK REDUCTION; ROUTINE IMMUNIZATION; SINGLE DRUG DOSE; SUPPLEMENTAL IMMUNIZATION ACTIVITY; VIRUS TRANSMISSION; COMPUTER SIMULATION; DISEASE ERADICATION; IMMUNOLOGY; PROCEDURES; VACCINATION;

COMPUTER SIMULATION; DISEASE ERADICATION; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84910623641     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit838     Document Type: Article

References (39)

1. World Health Organization. Cessation of Routine Oral Polio Vaccine (OPV) use after Global Polio Eradication: framework for national policy makers in OPV-using cou ntries. WHO/POL/05.02. Geneva, Switzerland, 2005.
2. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26:1471-505.
3. World Health Organization. Transmission of wild poliovirus type 2-Apparent global interruption. Wkly Epidemiol Rec 2001; 76:95-7.
4. World Health Organization. Global Polio Eradication Initiative-List of wild poliovirus by country. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx. Accessed 24 September 2013.
5. World Heal th Organization Polio Eradication and Endgame Strategic Plan 2013-2018. http://www.polioeradication.org/resourcelibrary/strategyandwork.aspx. 2013. Accessed 6 January 2014.
6. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368: 416-24.
7. Duintjer Tebbens RJ, Pallansch MA, Kal kowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccinerelated polioviruses. Risk Anal 2013; 23:703-49.
8. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SFG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis 2014; 14:45.
9. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014; 210(suppl 1):S475-84.
10. Duintjer Tebbens RJ, Pallansch M A, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013; 33:544-605.
11. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Review and asses sment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013; 33:606-46.
12. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassila k SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013; 33:647-63.
13. Benyesh-Melnick M, Melnick JL, Rawls WE, et al. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 1967; 86: 112-36.
14. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA 1996; 275:1639-45.
15. M ás Lago P,Bravo JR,Andrus JK,et al. Lesson from Cuba: mass campaign admini stration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ 1994 72, 221-5.
16. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004; 292:1696-701.
17. Kohler KA, Banerjee K, Gary HladyW, Andrus JK, Sutter RW. Vaccineassociated paralytic po liomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002; 80:210-6.
18. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pal lansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 2005; 59:587-635.
19. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9.
20. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, et al. Review: Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Anal 2013; 23:680-702.
21. Patriarca PA,Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
22. Thompson KM, Pallansch MA, Duintjer Tebbens RJ,Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013; 33:516-43.
23. Estivariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013; 3:309-15.
24. Onorat o IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163:1-6.
25. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathogens 2012; 8:e1002599.
26. Kalk owska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis 2014; 210 (suppl 1):S412-23.
27. Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol 1990; 28:365-82.
28. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis 2014; 21 0(suppl 1):S398-411.
29. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol 2005; 162: 358-72.
30. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public He alth 2008; 98:1322-30.
31. Oostvogel P, vanWijngaarden J, van der Avoort HG, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. Lancet 1994; 344:665-70.
32. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976- 1995. J Infect Dis 1997; 175(suppl 1):S165-72.
33. Marine WM, Chin TD, Gra velle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children: a family study during a type 1 poliomyelitis epidemic. Am J Hyg 1962; 76:173-95.
34. Ghendon YZ, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 1994; 72:973-83.
35. The Cuba IPV St udy Collaborative Group. Randomized, placebocontrolled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007; 356:1536-44.
36. Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveil 2013; 18:pii=20586.
37. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis 1984; 6:S457-S60.
38. Chin TD, Marine WM, Hall EC, Gravelle CR, Speers JF. Poliomyelitis in Des Moines, Iowa, 1959: the influence of Salk vaccination on the epidemic pattern and the spread of the virus in the community. Am J Hyg 1961; 74:67-94.
39. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccines. 2014; 13:221-234.